vs

Side-by-side financial comparison of BioAge Labs, Inc. (BIOA) and Roivant Sciences Ltd. (ROIV). Click either name above to swap in a different company.

BioAge Labs, Inc. is the larger business by last-quarter revenue ($3.1M vs $2.0M, roughly 1.5× Roivant Sciences Ltd.). BioAge Labs, Inc. runs the higher net margin — -842.9% vs -13301.2%, a 12458.3% gap on every dollar of revenue. BioAge Labs, Inc. produced more free cash flow last quarter ($-28.4M vs $-201.4M).

Altos Labs, Inc. is an American biotechnology research company. Altos Labs' goal is to develop life extension therapies that can halt or reverse the human aging process. Specialized cell therapies based on induced pluripotent stem cells are to be developed for this purpose. Russian-born technology businessman Yuri Milner, along with investors including Jeff Bezos, funded the company in 2021, operations started in 2022.

Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.

BIOA vs ROIV — Head-to-Head

Bigger by revenue
BIOA
BIOA
1.5× larger
BIOA
$3.1M
$2.0M
ROIV
Higher net margin
BIOA
BIOA
12458.3% more per $
BIOA
-842.9%
-13301.2%
ROIV
More free cash flow
BIOA
BIOA
$173.1M more FCF
BIOA
$-28.4M
$-201.4M
ROIV

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
BIOA
BIOA
ROIV
ROIV
Revenue
$3.1M
$2.0M
Net Profit
$-25.9M
$-265.9M
Gross Margin
Operating Margin
-923.4%
-16966.1%
Net Margin
-842.9%
-13301.2%
Revenue YoY
-77.8%
Net Profit YoY
-257.0%
EPS (diluted)
$-0.72
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOA
BIOA
ROIV
ROIV
Q4 25
$3.1M
$2.0M
Q3 25
$2.1M
$1.6M
Q2 25
$2.4M
$2.2M
Q1 25
$1.5M
$-39.6M
Q4 24
$9.0M
Q3 24
$0
$4.5M
Q2 24
$8.0M
Q1 24
$28.9M
Net Profit
BIOA
BIOA
ROIV
ROIV
Q4 25
$-25.9M
$-265.9M
Q3 25
$-20.2M
$-113.5M
Q2 25
$-21.6M
$-223.4M
Q1 25
$-12.9M
$-206.5M
Q4 24
$169.4M
Q3 24
$-23.4M
$-230.2M
Q2 24
$95.3M
Q1 24
$-151.1M
Operating Margin
BIOA
BIOA
ROIV
ROIV
Q4 25
-923.4%
-16966.1%
Q3 25
-1126.6%
-19492.9%
Q2 25
-1027.0%
-13130.0%
Q1 25
-1133.4%
674.8%
Q4 24
-3042.6%
Q3 24
-7636.0%
Q2 24
-1279.5%
Q1 24
-919.5%
Net Margin
BIOA
BIOA
ROIV
ROIV
Q4 25
-842.9%
-13301.2%
Q3 25
-982.0%
-7225.9%
Q2 25
-894.0%
-10292.9%
Q1 25
-891.0%
521.8%
Q4 24
1878.3%
Q3 24
-5143.8%
Q2 24
1192.7%
Q1 24
-522.3%
EPS (diluted)
BIOA
BIOA
ROIV
ROIV
Q4 25
$-0.72
$-0.38
Q3 25
$-0.56
$-0.17
Q2 25
$-0.60
$-0.33
Q1 25
$-0.36
$-0.28
Q4 24
$0.23
Q3 24
$-6.70
$-0.31
Q2 24
$0.12
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOA
BIOA
ROIV
ROIV
Cash + ST InvestmentsLiquidity on hand
$281.1M
$4.5B
Total DebtLower is stronger
Stockholders' EquityBook value
$272.1M
$4.3B
Total Assets
$294.9M
$5.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOA
BIOA
ROIV
ROIV
Q4 25
$281.1M
$4.5B
Q3 25
$285.8M
$4.4B
Q2 25
$297.3M
$4.5B
Q1 25
$320.5M
$4.9B
Q4 24
$5.1B
Q3 24
$334.5M
$5.4B
Q2 24
$5.7B
Q1 24
$6.5B
Total Debt
BIOA
BIOA
ROIV
ROIV
Q4 25
Q3 25
Q2 25
Q1 25
$7.1M
Q4 24
Q3 24
$9.9M
Q2 24
$311.7M
Q1 24
$430.6M
Stockholders' Equity
BIOA
BIOA
ROIV
ROIV
Q4 25
$272.1M
$4.3B
Q3 25
$277.5M
$4.4B
Q2 25
$294.8M
$4.3B
Q1 25
$313.2M
$4.7B
Q4 24
$5.2B
Q3 24
$313.7M
$5.2B
Q2 24
$5.4B
Q1 24
$6.0B
Total Assets
BIOA
BIOA
ROIV
ROIV
Q4 25
$294.9M
$5.2B
Q3 25
$305.1M
$5.1B
Q2 25
$322.1M
$5.0B
Q1 25
$343.8M
$5.4B
Q4 24
$5.8B
Q3 24
$337.4M
$6.2B
Q2 24
$6.5B
Q1 24
$7.2B
Debt / Equity
BIOA
BIOA
ROIV
ROIV
Q4 25
Q3 25
Q2 25
Q1 25
0.02×
Q4 24
Q3 24
0.03×
Q2 24
0.06×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOA
BIOA
ROIV
ROIV
Operating Cash FlowLast quarter
$-28.3M
$-196.5M
Free Cash FlowOCF − Capex
$-28.4M
$-201.4M
FCF MarginFCF / Revenue
-921.5%
-10076.0%
Capex IntensityCapex / Revenue
3.6%
246.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-82.3M
$-776.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOA
BIOA
ROIV
ROIV
Q4 25
$-28.3M
$-196.5M
Q3 25
$-16.0M
$-185.7M
Q2 25
$-20.0M
$-204.4M
Q1 25
$-17.4M
$-172.6M
Q4 24
$-207.3M
Q3 24
$-266.8M
Q2 24
$-192.8M
Q1 24
$-108.5M
Free Cash Flow
BIOA
BIOA
ROIV
ROIV
Q4 25
$-28.4M
$-201.4M
Q3 25
$-16.1M
$-193.5M
Q2 25
$-20.1M
$-208.4M
Q1 25
$-17.8M
$-173.4M
Q4 24
$-209.1M
Q3 24
$-267.8M
Q2 24
$-193.8M
Q1 24
$-108.8M
FCF Margin
BIOA
BIOA
ROIV
ROIV
Q4 25
-921.5%
-10076.0%
Q3 25
-782.2%
-12317.8%
Q2 25
-834.5%
-9604.5%
Q1 25
-1226.0%
438.1%
Q4 24
-2318.5%
Q3 24
-5984.4%
Q2 24
-2425.5%
Q1 24
-376.1%
Capex Intensity
BIOA
BIOA
ROIV
ROIV
Q4 25
3.6%
246.9%
Q3 25
1.1%
499.6%
Q2 25
6.6%
185.9%
Q1 25
29.4%
-2.0%
Q4 24
20.3%
Q3 24
22.3%
Q2 24
12.1%
Q1 24
1.2%
Cash Conversion
BIOA
BIOA
ROIV
ROIV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-1.22×
Q3 24
Q2 24
-2.02×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons